Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vildagliptin in subjects with impaired glucose tolerance
2005-002778-30Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prediabetes and type 2 diabetes mellitus (T2DM) comparing Vildagliptin 50 mg once daily with Placebo (2 arms). Primary endpoint: Change from baseline in prandial plasma glucose AUC0-2hr. Started Aug 2005; status: completed.
02
Drugs
vildagliptin
03
Conditions
prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-002778-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002778-30.